Innovation in Microbiological Testing.
Bactest has developed a microbial contamination testing technology platform "CYTOMAIA" which features rapid detection with all the benefits of an automated system but presented as an advanced modular design which is economical and practical for a broad range of applications.
Monitoring and control
Efficient monitoring of Microbial activity can contribute to improved control of biological processes in many industries, increasing productivity, while reducing costs, energy usage and carbon emissions.
BACTEST - Winner of the Technology Strategy Board "Disruptive solutions for sustainability problems" competition 2010
www.innovate10.co.uk/live
Use link and scroll to see Prof. Annie Brooking present.
Keep Up-To-Date
Latest News
News and Updates
BACTEST Closes £900k Funding Round
Thursday, January 26 2012. UK based BACTEST Ltd. today announced that it had closed a £900k funding round led by the Low Carbon Innovation Fund (LCIF), managed by Turquoise International, which invested £300k in BACTEST.
Thursday, January 26 2012. UK based BACTEST Ltd. today announced that it had closed a £900k funding round led by the Low Carbon Innovation Fund (LCIF), managed by Turquoise International, which invested £300k in BACTEST.
Bactest creates new company for Health Sector
Bactest has created a wholly owned subsidiary to exploit its proprietory platform CYTOMAIA in the Human Health Sector. The new company GEMINI Diagnostics Ltd will focus on human clinical applications of CYTOMAIA.
Bactest has created a wholly owned subsidiary to exploit its proprietory platform CYTOMAIA in the Human Health Sector. The new company GEMINI Diagnostics Ltd will focus on human clinical applications of CYTOMAIA.